Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Rochester
ClinicalTrials.gov Identifier:
NCT00003356
First received: November 1, 1999
Last updated: October 14, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2002
  Primary Completion Date: May 2002 (Final data collection date for primary outcome measure)